Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.
Funding
$27M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Complex diseases involve intricate networks of genetic interactions, making it difficult to identify effective drug targets and predict patient response to treatment. Traditional drug discovery methods often fail to account for this complexity, leading to high failure rates and limited therapeutic options for many solid tumors.
Solution
Engine Biosciences employs a platform that integrates machine learning and high-throughput biology to decipher complex disease networks and pinpoint key genetic interactions. This approach enables the identification of novel drug targets, the development of targeted therapeutics, and the discovery of biomarkers for patient selection. By understanding the underlying biology of diseases at a systems level, Engine Biosciences aims to accelerate the development of precision medicines and improve clinical outcomes for specific patient populations with solid tumors. The company focuses on designing, selecting, and developing therapeutics tailored to specific clinical contexts, while also partnering to expand the impact of its platform and assets.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians focused on developing and delivering precision medicines for cancer patients.
Features
- Machine learning algorithms to analyze large-scale biological datasets and identify genetic interactions within disease networks.
- High-throughput biological assays to validate computational predictions and characterize the function of identified targets.
- Identification of biomarkers for patient stratification and prediction of treatment response.
- Development of targeted therapeutics that modulate key nodes in disease networks.
- A repeatable platform for discovering and developing new medicines across a range of solid tumors.